KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Total Liabilities (2016 - 2025)

NovoCure's Total Liabilities history spans 12 years, with the latest figure at $463.9 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 47.32% year-over-year to $463.9 million; the TTM value through Dec 2025 reached $463.9 million, down 47.32%, while the annual FY2025 figure was $463.9 million, 47.32% down from the prior year.
  • Total Liabilities for Q4 2025 was $463.9 million at NovoCure, down from $1.0 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $1.0 billion in Q3 2025 and bottomed at $463.9 million in Q4 2025.
  • The 5-year median for Total Liabilities is $746.9 million (2022), against an average of $769.5 million.
  • The largest annual shift saw Total Liabilities soared 470.34% in 2021 before it plummeted 47.32% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $729.0 million in 2021, then increased by 2.95% to $750.5 million in 2022, then rose by 4.42% to $783.6 million in 2023, then rose by 12.37% to $880.6 million in 2024, then tumbled by 47.32% to $463.9 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Total Liabilities are $463.9 million (Q4 2025), $1.0 billion (Q3 2025), and $896.4 million (Q2 2025).